Publication: Assessing the value of moderate‐to‐severe atopic dermatitis treatment using multi‐criteria decision analysis (MCDA)
No Thumbnail Available
Identifiers
Date
2024-01-01
Authors
Pereyra-Rodriguez, Jose Juan
Poveda, José Luis
Rivero, Alvaro
Serra-Baldrich, Esther
Silvestre, Juan Francisco
Armario-Hita, José Carlos
Calleja, Miguel Angel
Carrascosa, Jose Manuel
Florez, Angeles
Herranz, Pedro
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley
Abstract
The increased understanding of atopic dermatitis (AD) pathophysiology has shed light on the underlying immunologic mechanisms and spurred the development of novel, more precisely targeted therapies. As new agents become available, assessing their added value is advisable. Yet the value of novel health interventions sometimes remains largely unmeasured and inadequately understood. Value assessment is challenging since it involves assessing the extent to which it meets current unmet needs. Therefore, it is necessary to establish the most relevant health outcomes from different stakeholders' perspectives.
Description
MeSH Terms
Decision Making
Decision Support Techniques
Dermatitis, Atopic
Decision Support Techniques
Dermatitis, Atopic
DeCS Terms
Dermatitis atópica
Análisis de decisión multicriterio
Calidad de vida relacionada con la salud
Reducción del prurito
Control de la actividad de la enfermedad
Análisis de decisión multicriterio
Calidad de vida relacionada con la salud
Reducción del prurito
Control de la actividad de la enfermedad
CIE Terms
Keywords
Atopic dermatitis, Multi‑criteria decision analysis (MCDA), Health-related quality of life (HRQoL), Pruritus reduction, Disease activity control
Citation
Pereyra‐Rodríguez JJ, Poveda JL, Rivero A, Serra‐Baldrich E, Silvestre JF, Armario‐Hita JC et al. Assessing the value of moderate‐to‐severe atopic dermatitis treatment using multi‐criteria decision analysis (MCDA). JEADV 2024;38:e59‐e62